Biggest News Aggregation in the World

Dermavant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dermavant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dermavant Sciences Today - Breaking & Trending Today

Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation

Published: May 27, 2024

/PRNewswire/ -- DelveInsight's Acne Vulgaris Market Insights report includes a comprehensive understanding of current treatment practices, acne vulgaris...

Source: prnewswire.com

Dermavant Sciences: Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD

Published: May 21, 2024

- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis

Source: finanznachrichten.de

Dermatology Month in Review: April 2024

Published: May 1, 2024

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

Source: hcplive.com

Tapinarof Cream for Adult, Pediatric Eczema Under FDA Review

Published: April 30, 2024

A decision on approval is expected in the fourth quarter of 2024.

Source: medscape.com

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Published: April 29, 2024

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Apr 29, 2024--

Source: eagletribune.com